Favipiravir is a broad-spectrum antiviral agent and selectively inhibits RNA polymerase of influenza virus and prevents viral replication. Favipiravir has proven efficacy against a wide range of influenza viruses, including strains resistant to existing anti-influenza drugs. Favipiravir 200 mg is approved by DCGI (Drugs Controller General of India) under accelerated approval process considering the emergency situation and unmet medical need in light of the COVID-19outbreak for restricted emergency use in the country. Favivent (Favipiravir 200 mg) can benefit patients showing mild-to-moderate symptoms of COVID-19. It will be available as a prescription-only drug and administered in the prescribed dosage under a certified practicing doctor’s supervision only with the informed consent of the patient. Please refer to the full prescribing information.

Favivent is manufactured in a plant compliant with US-FDA and EDQM standards.

Favipiravir 200 mg is approved by DCGI (Drugs Controller General of India) under accelerated approval process considering the emergency situation and unmet medical need in light of the COVID-19outbreak for restricted emergency use in the country.